Preview

谢切诺夫学报

高级搜索

Case report of metastatic colorectal cancer associated with KRAS A146V and A59G mutations

https://doi.org/10.47093/2218-7332.2023.14.2.49-56

摘要

In colorectal cancer (CRC) in addition to the most common mutations in the second exon of KRAS, there are rarer mutations that are not well understood as prognostic markers.

Description of cases. We describe two clinical cases of moderately differentiated adenocarcinoma (low-grade, G2), which manifested a complicated course in a 67-year-old woman – intestinal obstruction (case 1) and in a 62-year-old man – paratumorous abscess (case 2). Both cases were characterized by the development of regional and distant metastases (liver, brain) and a short relapse-free period. We found rare sporadic mutations of KRAS A146V and A59G with microsatellite stability and no mutation in the V600 BRAF site.

Discussion. In the presented case 1, the KRAS A146V mutation was detected, the frequency of its detection in our practice of testing 2103 cases of CRC was 0.48%. Case 2 shows the extremely rare A59G mutation. Among the patients with CRC we studied, we found mutations in codon 59 in only two, which amounted to 0.095%. Both rare mutations represent separate molecular subgroups of CRC, characterized by an unfavorable clinical outcome and requiring the development of special treatment regimens.

关于作者

O. Kit
National Medical Research Centre for Oncology
俄罗斯联邦


N. Timoshkina
National Medical Research Centre for Oncology
俄罗斯联邦


D. Gvaldin
National Medical Research Centre for Oncology
俄罗斯联邦


N. Soldatkina
National Medical Research Centre for Oncology
俄罗斯联邦


Yu. Gevorkyan
National Medical Research Centre for Oncology
俄罗斯联邦


参考

1. Hofmann M.H., Gerlach D., Misale S., et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022 Apr 1; 12(4): 924–937. https://doi.org/10.1158/2159-8290.CD-21-1331. PMID: 35046095

2. Кит О.И., Геворкян Ю.А., Солдаткина Н.В. и др. Современные прогностические факторы при колоректальном раке. Колопроктология. 2021; 20(2): 42–49. https://doi.org/10.33878/20737556-2021-20-2-42-49. EDN: OUYFX

3. Giopanou I., Pintzas A. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Crit Rev Oncol Hematol. 2020 Feb; 146: 102859. Epub 2019 Dec 17. https://doi.org/10.1016/j.critrevonc.2019.102859. PMID: 31927392

4. Zhu C., Guan X., Zhang X., et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. ol Cancer. 2022 Aug 4; 21(1): 159. https://doi.org/10.1186/s12943-022-01629-2. PMID: 35922812

5. Malumbres M., Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3(6): 459–465. https://doi.org/10.1038/nrc1097

6. Hong D.S., Fakih M.G., Strickler J.H., et al. KRAS inhibition with SotoRASib in advanced solid tumors. Engl J Med. 2020 Sep 24; 383(13): 1207–1217. https://doi.org/10.1056/NEJMoa1917239. Epub 2020 Sep 20. PMID: 32955176

7. Wang X., Allen S., Blake J.F., et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS inhibitor. J Med Chem. 2022 Feb 24; 65(4): 3123–3133. https://doi.org/10.1021/acs.jmedchem.1c01688 Epub 2021 Dec 10. PMID: 34889605

8. Кит О.И., Дженкова Е.А., Мирзоян Э.А. и др. Молекулярногенетическая классификация подтипов колоректального рака: современное состояние проблемы. Южно-Российский онкологический журнал. 2021; 2(2): 50–56. https://doi.org/10.37748/2686-9039-2021-2-2-6

9. Araki M., Shima F., Yoshikawa Y., et al. Solution structure of the state 1 conformer of GTP-bound H-RAS Protein and distinct dynamic properties between the state 1 and state 2 conformers. J Biol Chem. 2011 Nov 11; 286(45): 39644–39653. https://doi.org/10.1074/jbc.M111.227074. Epub 2011 Sep 19. PMID: 21930707

10. Zhu C., Guan X., Zhang X., et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer. 2022 Aug 4; 21(1): 159. https://doi.org/10.1186/s12943-022-01629-2. PMID: 35922812

11. Van’t Erve I., Wesdorp N.J., Medina J.E., et al. KRAS A146 mutations are associated with distinct clinical behavior in patients with colorectal liver metastases. JCO Precis Oncol. 2021 Nov 17; 5: PO.21.00223. https://doi.org/10.1200/PO.21.00223. PMID: 3482059

12. Lu J., Bera A.K., Gondi S., Westover K.D. KRAS Switch Mutants D33E and A59G crystallize in the state 1 conformation. Biochemistry. 2018 Jan 23; 57(3): 324–333. https://doi.org/10.1021/acs.biochem.7b00974. Epub 2017 Dec 28. PMID: 29235861

13. Zhao J., Wang L., Bao H., Chen J. Cluster analysis on conformational changes of the GDP/KRAS complex induced by A59G and D33E. Chemical Physics Letters, 16 October 2021; 781: 138995. https://doi.org/10.1016/j.cplett.2021.138995


补充文件

1. CARE checklist
主题
类型 Исследовательские инструменты
下载 (148KB)    
索引源数据 ▾

评论

浏览: 2970


ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)